Esophageal carcinoma (squamous + adeno) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-BARRETTS-ESOPHAGUS-PREVENTION-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-ESOPHAGEAL`
Sources	`SRC-ESMO-ESOPHAGEAL-2024` `SRC-NCCN-ESOPHAGEAL-2025`

Notes

STUB — v0.3 chronic-condition prevention pilot (Barrett's esophagus). Two-Co-Lead signoff queued. Aspirin-chemoprevention controversy (AspECT) currently in rationale; may become a dedicated known_controversies entry once a SRC entity for the AspECT trial is authored. Sources TODO: ACG Barrett's Esophagus Clinical Guideline 2022 (Shaheen et al.) and AGA Barrett's Esophagus Clinical Practice Update 2022 as new SRC entities — primary guideline citations for Seattle biopsy protocol, RFA cadence, and CE-IM endpoint definitions. Engine smoke-tested (worktree feat/chronic-condition-prevention- 2026-05-18): RF-BARRETTS-ESOPHAGUS-PREVENTION fires and routes to 2 PreventionPlan tracks (this Indication as default + observation alternative).

Used By

Algorithms

ALGO-PREVENTION-RISK-TRIAGE-OVERVIEW - ALGO-PREVENTION-RISK-TRIAGE-OVERVIEW

Indication

IND-BARRETTS-ESOPHAGUS-PREVENTION-OBSERVATION - IND-BARRETTS-ESOPHAGUS-PREVENTION-OBSERVATION

Red flag

RF-BARRETTS-ESOPHAGUS-PREVENTION - Barrett's esophagus (intestinal metaplasia of the distal esophagus with goblet cells on b...